Novel biotoxin being studied for use in opioid withdrawal

Vancouver-On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants. This double-blind, randomized, cross-over, placebo-controlled trial will evaluate the efficacy and safety of Tetrodin for treatment withdrawal symptoms in 20 opiate-dependent subjects who are receiving methadone in a treatment program. It is the first study involving a biotoxin for opioid withdrawal to be done in North America.

Use of opioids presents many challenges for the addicts, their families, and society as a whole. The health and social consequences include HIV/AIDS, Hepatitis B, and C, tuberculosis, fetal effects, violence, and crime. Family life, workplace, and educational environments are all affected, with associated costs reaching billions of dollars each year.

"There's a need for new treatments for heroin dependence and for opiate abuse, and this is one potential new approach, directed at modifying the physical dependence that occurs with repeated use of drugs like heroin," said Dr. Edward Sellers President and CEO of Ventana Clinical Research Corporation. Dr. Sellers is the lead investigator on the study, and is a member of numerous national and international editorial boards, governmental advisory committees, and international organizations including the World Health Organization Expert Advisory Committee on Drug Dependence.

What is Opioid Dependence - Why use a Biotoxin?

Opioid dependence is generally characterized by a withdrawal syndrome that occurs when the drug is abruptly discontinued. Managing withdrawal is essential in enabling people to begin treatment programs to end their opioid dependence. The traditional medical management of opioid withdrawal involves substituting long-acting opioids for shorter-acting opioids, and gradually tapering the treatment.

However, unlike traditional therapies Tetr

Contact: Don Evans
WEX Pharmaceuticals Inc.

Page: 1 2

Related biology news :

1. Novel sugar-to-hydrogen technology promises transportation fuel independence
2. Novel system developed to turn data into real-time, interactive 3-D images
3. Novel strategies for healthy aging
4. Novel salamander robot crawls its way up the evolutionary ladder
5. Novel test identifies lymphoma patients likely to respond to new therapy
6. Novel laboratory technique nudges genes into activity
7. Novel approaches to tackling obesity, cancer and MRSA
8. Novel approach to cancer drug given major boost
9. Novel regulation of the common tumor suppressor PTEN
10. Novel EGFR ectodomain mutations in glioblastoma
11. Novel regulatory mechanism identified for key tumor suppressor p53

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: